News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fresenius Kabi Pharmaceuticals Holding, Inc. Release: APP Pharmaceuticals To Market Anastrozole Tablets In The U.S.


6/29/2010 7:49:10 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited (NSE:FKONCO) (BSE:532545). APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Anastrozole is therapeutically equivalent to the reference-listed drug Arimidex®, which is currently marketed by the innovator AstraZeneca.

Read at BioSpace.com


comments powered by Disqus
   
Menopause

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES